1.Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Ajit SOOD ; Vineet AHUJA ; Vandana MIDHA ; Saroj Kant SINHA ; C. Ganesh PAI ; Saurabh KEDIA ; Varun MEHTA ; Sawan BOPANNA ; Philip ABRAHAM ; Rupa BANERJEE ; Shobna BHATIA ; Karmabir CHAKRAVARTTY ; Sunil DADHICH ; Devendra DESAI ; Manisha DWIVEDI ; Bhabhadev GOSWAMI ; Kirandeep KAUR ; Rajeev KHOSLA ; Ajay KUMAR ; Ramit MAHAJAN ; S. P. MISRA ; Kiran PEDDI ; Shivaram Prasad SINGH ; Arshdeep SINGH
Intestinal Research 2020;18(4):355-378
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
Result Analysis
Print
Save
E-mail